1
|
Liu Z, Han X, You Y, Xin G, Li L, Gao J, Meng H, Cao C, Liu J, Zhang Y, Li L, Fu J. Shuangshen ningxin formula attenuates cardiac microvascular ischemia/reperfusion injury through improving mitochondrial function. JOURNAL OF ETHNOPHARMACOLOGY 2024; 323:117690. [PMID: 38195019 DOI: 10.1016/j.jep.2023.117690] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/04/2023] [Revised: 12/27/2023] [Accepted: 12/28/2023] [Indexed: 01/11/2024]
Abstract
ETHNOPHARMACOLOGICAL RELEVANCE Shuangshen Ningxin Formula (SSNX) is a traditional Chinese medicine formula used to treat myocardial ischemia-reperfusion injury (MIRI). A randomized controlled trial previously showed that SSNX reduced cardiovascular events, and experiments have also verified that SSNX attenuated ischemia-reperfusion (I/R) injury. However, the mechanism of SSNX in the treatment of microvascular I/R injury is still unclear. AIM OF THE STUDY To determine whether SSNX protects the microvasculature by regulating I/R induction in rats and whether this effect depends on the regulation of NR4A1/Mff/Drp1 pathway. METHODS The anterior descending coronary artery was ligated to establish a rat MIRI model with 45 min of ischemia and 24 h of reperfusion. The rats were subjected to a 7-day pretreatment with SSNX and nicorandil, after which their cardiac function and microvascular functional morphology were evaluated through diverse methods, including hematoxylin and eosin (HE) staining, wheat germ agglutinin (WGA) staining, and transmission electron microscopy. Cell apoptosis was assessed using terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining. Additionally, serum levels of ET-1 and eNOS were determined through an enzyme-linked immunosorbent assay (ELISA). The expression levels of NR4A1, Mff, and proteins related to mitochondrial fission were examined by Western blot (WB). Cardiac microcirculation endothelial cells (CMECs) were cultured and the oxygen-glucose deprivation/reoxygenation (OGD/R) model was duplicated. Following treatment with SSNX and DIM-C-pPhOH, an NR4A1 inhibitor, cell viability was assessed. Fluorescence was used to evaluate mitochondrial membrane potential (MMP) and mitochondrial permeability transition pore (MPTP) opening. Moreover, vascular endothelial function was evaluated through transendothelial electrical resistance (TEER), Transwell assays and tube formation assays. RESULTS The results showed that SSNX reduced the infarction area and no-flow area, improved cardiac function, mitigated pathological alterations, increased endothelial nitric oxide synthase expression, protected endothelial function, and attenuated microvascular damage after I/R injury. I/R triggered mitochondrial fission and apoptotic signaling in CMECs, while SSNX restored mitochondrial fission to normal levels and inhibited mitochondrial apoptosis. A study using CMECs revealed that SSNX protected endothelial function after OGD/R, attenuating the increase in NR4A1/Mff/Drp1 protein and inactivating VDAC1, HK2, cytochrome c (cyt-c) and caspase-9. Research also shows that SSNX can affect CMEC cell migration and angiogenesis, reduce mitochondrial membrane potential damage, and inhibit membrane opening. Moreover, DIM-C-pPhOH, an NR4A1 inhibitor, partially imitated the effect of SSNX. CONCLUSION SSNX has a protective effect on the cardiac microvasculature by inhibiting the NR4A1/Mff/Drp1 pathway both in vivo and in vitro.
Collapse
Affiliation(s)
- ZiXin Liu
- Institute of Basic Medical Sciences of Xiyuan Hospital, China Academy of Chinese Medical Sciences, National Clinical Research Center for Cardiovascular Diseases of Traditional Chinese Medicine, Beijing 100091, PR China.
| | - Xiao Han
- Institute of Basic Medical Sciences of Xiyuan Hospital, China Academy of Chinese Medical Sciences, National Clinical Research Center for Cardiovascular Diseases of Traditional Chinese Medicine, Beijing 100091, PR China.
| | - Yue You
- Institute of Basic Medical Sciences of Xiyuan Hospital, China Academy of Chinese Medical Sciences, National Clinical Research Center for Cardiovascular Diseases of Traditional Chinese Medicine, Beijing 100091, PR China.
| | - GaoJie Xin
- Institute of Basic Medical Sciences of Xiyuan Hospital, China Academy of Chinese Medical Sciences, National Clinical Research Center for Cardiovascular Diseases of Traditional Chinese Medicine, Beijing 100091, PR China.
| | - LingMei Li
- Institute of Basic Medical Sciences of Xiyuan Hospital, China Academy of Chinese Medical Sciences, National Clinical Research Center for Cardiovascular Diseases of Traditional Chinese Medicine, Beijing 100091, PR China.
| | - JiaMing Gao
- Institute of Basic Medical Sciences of Xiyuan Hospital, China Academy of Chinese Medical Sciences, National Clinical Research Center for Cardiovascular Diseases of Traditional Chinese Medicine, Beijing 100091, PR China.
| | - HongXu Meng
- Institute of Basic Medical Sciences of Xiyuan Hospital, China Academy of Chinese Medical Sciences, National Clinical Research Center for Cardiovascular Diseases of Traditional Chinese Medicine, Beijing 100091, PR China.
| | - Ce Cao
- Institute of Basic Medical Sciences of Xiyuan Hospital, China Academy of Chinese Medical Sciences, National Clinical Research Center for Cardiovascular Diseases of Traditional Chinese Medicine, Beijing 100091, PR China.
| | - JianXun Liu
- Institute of Basic Medical Sciences of Xiyuan Hospital, China Academy of Chinese Medical Sciences, National Clinical Research Center for Cardiovascular Diseases of Traditional Chinese Medicine, Beijing 100091, PR China.
| | - YeHao Zhang
- Institute of Basic Medical Sciences of Xiyuan Hospital, China Academy of Chinese Medical Sciences, National Clinical Research Center for Cardiovascular Diseases of Traditional Chinese Medicine, Beijing 100091, PR China.
| | - Lei Li
- Institute of Basic Medical Sciences of Xiyuan Hospital, China Academy of Chinese Medical Sciences, National Clinical Research Center for Cardiovascular Diseases of Traditional Chinese Medicine, Beijing 100091, PR China.
| | - JianHua Fu
- Institute of Basic Medical Sciences of Xiyuan Hospital, China Academy of Chinese Medical Sciences, National Clinical Research Center for Cardiovascular Diseases of Traditional Chinese Medicine, Beijing 100091, PR China.
| |
Collapse
|
2
|
Zhang T, Liu L, Chen Q, Wang Y, Gao X, Ma X, Yan P. Comparative Assessment of In Vitro Xanthine Oxidase and α-Glucosidase Inhibitory Activities of Cultured Cambial Meristematic Cells, Adventitious Roots, and Field-Cultivated Ginseng. Nutrients 2024; 16:443. [PMID: 38337727 PMCID: PMC10857066 DOI: 10.3390/nu16030443] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2023] [Revised: 01/16/2024] [Accepted: 01/19/2024] [Indexed: 02/12/2024] Open
Abstract
Panax ginseng, a traditional Chinese medicine with a history spanning thousands of years, faces overexploitation and challenges related to extended growth periods. Tissue-cultured adventitious roots and stem cells are alternatives to wild and field-cultivated ginseng. In this study, we assessed the in vitro xanthine oxidase and α-glucosidase inhibitory activities of saponin extracts among cultured cambial meristematic cells (CMC), adventitious ginseng roots (AGR), and field-cultivated ginseng roots (CGR). The xanthine oxidase (XO) and α-glucosidase inhibitory activities were determined by uric acid estimation and the p-NPG method, respectively. Spectrophotometry and the Folin-Ciocalteu, aluminum nitrate, and Bradford methods were employed to ascertain the total saponins and phenolic, flavonoid, and protein contents. The calculated IC50 values for total saponin extracts against XO and α-glucosidase were 0.665, 0.844, and >1.6 mg/mL and 0.332, 0.745, and 0.042 mg/mL for AGR, CMC, CGR, respectively. Comparing the total saponin, crude protein, and total phenolic contents revealed that AGR > CMC > CGR. To the best of our knowledge, this study presents the first report on the in vitro comparison of xanthine oxidase and α-glucosidase inhibitory activities among AGR, CMC, and CGR. The findings offer valuable insights into the development of hypoglycemic and antihyperuricemic medicinal, nutraceutical, and functional products utilizing AGR and CMC.
Collapse
Affiliation(s)
- Tianhe Zhang
- School of Marine Science and Technology, Harbin Institute of Technology, Weihai 264209, China; (T.Z.); (Q.C.)
| | - Lijun Liu
- School of Marine Science and Technology, Harbin Institute of Technology, Weihai 264209, China; (T.Z.); (Q.C.)
| | - Qiqi Chen
- School of Marine Science and Technology, Harbin Institute of Technology, Weihai 264209, China; (T.Z.); (Q.C.)
| | - Yifei Wang
- School of Marine Science and Technology, Harbin Institute of Technology, Weihai 264209, China; (T.Z.); (Q.C.)
| | - Xiujun Gao
- School of Marine Science and Technology, Harbin Institute of Technology, Weihai 264209, China; (T.Z.); (Q.C.)
| | - Xingyi Ma
- School of Science, Harbin Institute of Technology, Shenzhen 518055, China
- Biosen International, Jinan 250117, China
- Briteley Institute of Life Sciences, Yantai 264003, China
- Shandong Key Laboratory of Biochemical Analysis, College of Chemistry and Molecular Engineering, Qingdao University of Science and Technology, Qingdao 266042, China
| | - Peisheng Yan
- School of Marine Science and Technology, Harbin Institute of Technology, Weihai 264209, China; (T.Z.); (Q.C.)
| |
Collapse
|